Press Releases
Events
News Archive

 

 

DOBI Medical International Expands Distribution Network to Canada, Italy and Russia

Return to Press Releases

Mahwah, NJ, November 9,  2004 - DOBI Medical International, Inc. (OTCBB:DBMI) announced today that it signed distribution agreements for the ComfortScan™ system with several leading medical suppliers including Horizon Medical Services Ltd. in Ontario, Canada; Technologic s.r.l. in Torino, Italy; and SouzMedTechnika, Moscow, Russia. The ComfortScan system is a non-invasive, non-ionizing, and gentle dynamic optical imaging tool designed to assist physicians in the detection and management of breast cancer.

Under the terms of the agreements, each distributor is required to place an initial purchase order for a ComfortScan system before the end of 2004 and to conduct an initial clinical trial within their respective regions.

"Experienced medical distributors like Horizon, Technologic and SouzMedTechnika are ideal business partners for DOBI Medical because they bring local market expertise as well as excellent reputations as cutting-edge suppliers in the medical technology industry within their respective countries,"said Denis A. O'Connor, Senior Vice President of Marketing, Sales and Service. "Upon successful completion of the local trials, we expect the ComfortScan system to be commercially available for sale in Canada, Italy and Russia. In addition, we have increasing interest from a number of other international business partners for this product. These new agreements represent another milestone for DOBI Medical in the international arena."

Larry Riley, president of Horizon Medical Services, stated, "We are very pleased to represent the DOBI Medical International product line in Canada. By combining the strong technical support of DOBI Medical in partnership with Horizon Medical's presence in the Canadian market, we are confident of future successes. The addition of the ComfortScan non-invasive system to our Women's Healthcare product line will greatly enhance our dedication in providing leading-edge technology for the clinical diagnostician."

Andrei Fedorov, director general of SouzMedTechnika, commented, "We are looking forward to introducing this device to top oncologists, doctors, private clinics and public hospitals, but most importantly, to all women throughout Russia. This is a unique device without any analogues in the medical device universe. This technology and state-of-the-art device are long overdue."

About DOBI Medical International, Inc.

DOBI Medical is a development stage medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization ("angiogenesis") associated with tumors. DOBI Medical International's first application of the technology is the ComfortScan system, a gentle, non-invasive, and non-ionizing, optical imaging system designed to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that are not readily available today. The ComfortScan system is an investigational device and is not commercially available in the United States.

Can You Buy Weed Online

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

Statements contained in this press release may contain information that includes or is based upon certain "forward-looking statements" relating to our business. These forward-looking statements represent management's current judgment and assumptions, and can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are frequently accompanied by the use of such words as "anticipates," "plans," "believes," "expects," "projects," "intends," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, including without limitation, those relating to our ability to timely and successfully complete our patient clinical trials; our ability to timely and successfully complete and submit our premarket approval application to the FDA; the timely and final approval by the FDA of our ComfortScan system as a adjunct to mammography, which approval in the U.S. cannot be assured; our ability to secure the additional financing adequate to execute our business plan; the success of product development and research efforts; our ability to timely meet U. S. and foreign government laws and industry standards; our ability to meet U.S. and foreign medical device quality regulation standards required to maintain our CE Mark, ISO, UL and FDA export certifications; our ability to timely deliver our products into international markets; the acceptance and use of our ComfortScan system by physicians, imaging clinics, and patients; our ability to meet the performance milestones and obtain the funding to close on the second tranche of the private placement completed in December, 2003; and our ability to obtain third party reimbursement from U.S. and foreign government and private payers.
Any one of these or other risks, uncertainties, other factors, or any inaccurate assumptions may cause actual results to be materially different from those described herein or elsewhere by us. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read and consider, including our 2003 Annual Report on Form 10-KSB, our Second Quarter Report 2004 on Form 10-QSB, and our Registration Statement on Form SB-2 declared effective September 27, 2004, all of which may be accessed from our website at igaot.pt. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Return to Press Releases

For further information:
Please contact: Michael Jorgensen, Chief Financial Officer
201-760-6464
mike@igaot.pt

DOBI Medical International
1200 MacArthur Blvd.
Mahwah, New Jersey 07430
Voice: (201) 760 6464
Fax: (201) 760 8860
e-mail: information@igaot.pt

 
 


calendario | newsletter | relacoes | atribuicoes | acidentesincidentes | legisot | reflegisd | apresentacao | missao | contactos
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5